Eton Pharmaceutical ETON
$60.85 −$0.51 (-0.83%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $60.85 0.00%
Open$61.00
Prev close$61.36
Day range$59.18 – $61.65
Volume562.7K
Market cap$1.76B
P/E (TTM)39.5
Dividend yield–
ETON Stock News
Headlines matching Eton Pharmaceutical or the ETON ticker, most recent first.
- Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO (Miltefosine) Capsules
- Eton Pharmaceutical(ETON.US) Officer Sells US$6.09 Million in Common Stock
- Upgrade: Analysts Just Made A Notable Increase To Their Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Forecasts Positive
- B. Riley Adjusts Price Target on Eton Pharmaceuticals to $70 From $40, Maintains Buy Rating
- H.C. Wainwright Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Raises Target Price to $70 Positive
- Craig-Hallum Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Raises Target Price to $76 Positive
- Craig-Hallum Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Maintains Target Price $62
- H.C. Wainwright Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Raises Target Price to $65 Positive
- 4: Eton Pharmaceutical | 4: Statement of changes in beneficial ownership of securities-10% Owner Opaleye Management Inc.
- CCORF Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Maintains Target Price $60
- Craig-Hallum Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Announces Target Price $62
- 4/A: Eton Pharmaceutical | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-10% Owner Opaleye Management Inc.
- CCORF Initiates Eton Pharmaceutical(ETON.US) With Buy Rating, Announces Target Price $60
- 4: Eton Pharmaceutical | 4: Statement of changes in beneficial ownership of securities-10% Owner Opaleye Management Inc.
- B. Riley Securities Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Maintains Target Price $40
No comments yet — be the first to weigh in on ETON.
Sign in to join the discussion.